Gene therapy for
advanced coronary artery disease

XyloCor Therapeutics is focused on improving the lives of patients through our commitment to advancing novel therapies for coronary artery disease.

Latest News

Press Release: March 5, 2026
XyloCor Appoints John Tucker as President and Chief Executive Officer
More >>

See Our Pipeline

XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>

Active Clinical Trial

XyloCor is actively recruiting patients living with chronic angina for its EXACT‑2 study, across sites in the US and Europe.
More >>